- Phase 1b/2 dose escalation trial of AST-008 shows tolerability of Exicure drug candidate - Preliminary data show signs of activity in patients with Merkel cell carcinoma - Exicure to proceed to Phase 2 study in Merkel cell carcinoma Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic… Read More..

Ms. Jenny has 20+ Years of Senior Financial Expertise NEW YORK, NY, Dec. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- PeerStream, Inc. (“PeerStream,” the “Company,” “we,” “our” or “us”) (PEER), a communications software innovator developing enhanced security and privacy solutions for multimedia communication and data transmission, today announced the… Read More..

Long Beach, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that data generated by StemoniX, Inc., using their proprietary microBrain® 3D platform, demonstrated that the proprietary analog of… Read More..